Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Oxford BioDynamics in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 36.30.
Current Consensus is
The current consensus among 0 polled investment analysts is to n/a stock in Oxford BioDynamics. This N/A consensus rating has held steady for over two years.
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use within the pharmaceutical and biotechnology industry primarily in the United states and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures. It has collaboration agreements with University of Glasgow for prognostic and predictive profiling of COVID-19 patients in the GETAFIX. Oxford BioDynamics Plc was founded in 2007 and is headquartered in Oxford, the United Kingdom.